Apimeds Pharmaceuticals US (APUS) Shares Outstanding (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Shares Outstanding (Entity) for 4 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 45.54% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (up 45.54% YoY), and the FY2025 full-year result was $1.3 million, up 59.11% from the prior year.
• Shares Outstanding (Entity) rose to $1.5 million in Q2 2026 per APUS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $1.5 million in Q2 2026 and bottomed at $459826.0 in Q4 2023.
• Historically, Shares Outstanding (Entity) has averaged $947297.8 across 4 years, with a median of $790385.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) surged 71.89% in 2024, then changed 0.0% in 2025.
• Over 4 years, Shares Outstanding (Entity) stood at $459826.0 in 2023, then soared by 71.89% to $790385.0 in 2024, then surged by 59.11% to $1.3 million in 2025, then climbed by 20.0% to $1.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.5 million, $1.3 million, and $1.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.